Case Report Featuring Ultra-Thick Amniotic Membrane Allograft for Treatment of Traumatic, Complex Wound Presented at SAWC Spring 2023

Orthopaedic Trauma Surgeon Highlights Efficacy of BioTissue Neox® 1K in Treating Patient with Lower Extremity Injury Sustained in Motorcycle Accident

MIAMI, April 27, 2023—At Symposium on Advanced Wound Care (SAWC) Spring 2023, an orthopaedic trauma surgeon will present a poster demonstrating the effectiveness of BioTissue Neox® 1K in the treatment of a traumatic, complex wound case.

Christopher Stewart, MD, of Baptist Medical Center in Little Rock, Ark., utilized the ultra-thick Amniotic Membrane (AM) allograft to treat a traumatic cavity wound sustained by a 39-year-old patient in a high-speed motorcycle accident.

In the case study, Dr. Stewart reports that the patient presented with multiple traumatic injuries, including ipsilateral open fractures of the femur, tibial shaft and plafond, a femoral neck fracture, and a large complex wound nearly circumferential around the knee. He noted that these wounds are particularly difficult to treat as they are more susceptible to infection, necrosis, and osteomyelitis—all of which are risk factors for limb loss. To expedite wound healing and reduce risk of complications, Dr. Stewart utilized a Neox® 1K ultra-thick AM allograft as a wound covering and shows the patient’s progress over the course of 34 weeks.

Dr. Stewart concluded that the ultra-thick AM allograft was shown to support wound closure for a traumatic, complex wound over a joint that had exposed nerve, artery, and tendons.

“Dr. Stewart’s case demonstrates the unmatched power of amniotic tissue in creating a protective environment for regenerative healing to occur in even the most traumatic, complex wounds. For this patient, BioTissue Neox® 1K very well may have prevented amputation, helping to restore life after surgery,” said Ted Davis, CEO, BioTissue. “It is a privilege to partner with physicians to elevate the standard of wound care, and ultimately, the quality of life for their patients.”

Dr. Stewart’s poster, Treatment of a Traumatic, Complex Wound Using Ultra-Thick Amniotic Membrane Allograft (entry CS-120), will be on display throughout the show at Gaylord National Resort and Convention Center in Prince George’s AB. The poster reception will be held on Friday, April 28 from 7:15 p.m. to 8:30 p.m.

About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 790,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.

Media Contact
Heather Kowalczyk
McDougall Communications for BioTissue
[email protected] or (585) 434-2148